Skip to main content

IP Update: Recent Patents, Patent Applications Awarded to Alnylam; OSU; City of Hope; and More

Premium

Title: Compositions and Methods for Inhibiting Expression of the Myc Gene

Patent Number: 8,124,752

Filed: July 9, 2007

Lead Inventor: David Bumcrot, Alnylam Pharmaceuticals

The invention, the patent's abstract states, relates to “a double-stranded ribonucleic acid for inhibiting the expression of the Myc gene.”

The dsRNA comprises “an antisense strand having a nucleotide sequence ... less than 30 nucleotides in length, generally 19 [to] 25 nucleotides in length, and which is substantially complementary to at least a part of the Myc gene,” it adds. “The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by Myc gene expression; and the expression of the Myc gene using the pharmaceutical composition.”


Title: Double-Stranded Nucleic Acid Molecule Cancer Cell Proliferation Inhibitor and Pharmaceutical Agent Suitable for Prevention or Treatment of Uterine Cancer, Breast Cancer, and Bladder Cancer

Patent Number: 8,124,754

Filed: Dec. 21, 2009

Lead Inventor: Satoshi Inoue, RNAi Co.

The patent, its abstract states, claims a “double-stranded nucleic acid molecule for suppressing the expression of at least one of COX7RP and Efp genes.”


Title: Compositions and Methods for Inducing an Immune Response in Mammal and Methods of Avoiding an Immune Response to Oligonucleotide Agents such as Short Interfering RNAs

Application Number: 20120045461

Filed: July 8, 2011

Lead Inventor: Gunther Hartmann, University Hospital Bonn

The invention, the patent application's abstract states, comprises “oligonucleotide agents that modulate an immune response by stimulating IFN production and methods of using such agents for therapeutic treatments of mammals.”


Title: Method for Diagnosing Acute Lymphomic Leukemia Using miR-221

Application Number: 20120046192

Filed: Oct. 17, 2011

Inventor: Carlo Croce, Ohio State University

The patent application, its abstract states, claims “compositions and methods for reducing the proliferation of ALL cancer cells through targeted interactions with ALL1 fusion proteins.”


Title: Method for Diagnosing Acute Lymphomic Leukemia Using miR-222

Application Number: 20120046193

Filed: Oct. 17, 2011

Inventor: Carlo Croce, Ohio State University

The patent application, its abstract states, claims “compositions and methods for reducing the proliferation of ALL cancer cells through targeted interactions with ALL1 fusion proteins.”


Title: Method for Diagnosing Acute Lymphomic Leukemia Using miR-146a

Application Number: 20120046194

Filed: Oct. 17, 2011

Inventor: Carlo Croce, Ohio State University

The patent application, its abstract states, claims “compositions and methods for reducing the proliferation of ALL cancer cells through targeted interactions with ALL1 fusion proteins.”


Title: Multi-Targeting Short Interfering RNAs

Application Number: 20120046343

Filed: Nov. 2, 2011

Lead Inventor: John Rossi, City of Hope

The invention, the patent application's abstract states, “relates to novel short interfering RNA molecules that are multi-targeted. More specifically, the ... invention relates to siRNA molecules that target two or more sequences. In one embodiment, multi-targeting siRNA molecules are designed to incorporate features of siRNA molecules and features of microRNA molecules. In another embodiment, multi-targeting siRNA molecules are designed so that each strand is directed to separate targets.”


Title: Down-Regulation of the Gene Expression by Means of Nucleic Acid-Loaded Virus-Like Particles

Application Number: 20120046340

Filed: Sept. 12, 2008

Lead Inventor: Jens Gruber, German Primate Center

The invention relates to “compositions of virus-like particles for the introduction of RNA interference-inducing molecules into eukaryotic cells and methods for the cell type-specific transduction of a plurality of eukaryotic cells with RNAi-inducing molecules,” the patent application's abstract states. The invention also relates to “methods for a diagnosis, prevention, and/or treatment of diseases or disease states associated with an increased expression rate of at least one endogenous gene, and/or with the undesired expression of at least one endogenous gene and/or foreign nucleic acids, in particular viral nucleic acids.”


Title: Lipid-Containing Formulations

Application Number: 20120046478

Filed: Aug. 16, 2011

Lead Inventor: Muthiah Manoharan, Alnylam Pharmaceuticals

The invention, the patent application's abstract states, comprises “compositions and methods useful in administering nucleic acid based therapies, for example association complexes such as liposomes and lipoplexes.”

The Scan

Gap in COVAX Doses

BBC News reports that COVAX is experiencing a vaccine shortfall, as the Serum Institute of India has paused exports.

Sanofi, GSK Report Promising Results

The Wall Street Journal reports that the candidate SARS-CoV-2 vaccine from Sanofi and GlaxoSmithKline has had encouraging early results.

Influence of Luck

The New York Times examines how the US avoided variant-fueled increases in COVID-19 cases.

PLOS Papers on Retina GWAS, Hantaan Virus, COVID-19 Phenome-Wide Association Study

In PLOS this week: genome-wide association study of retinal morphology, analysis of hantaan virus found in a mouse, and more.